Acrivon Therapeutics, Inc. (ACRV) Discusses ACR-525 Acquisition and PKC Inhibitor Preclinical Program Transcript

AI Summary

Acrivon Therapeutics discussed its acquisition of ACR-525 and a preclinical program involving a PKC inhibitor. The supplied transcript headline offers no further information about the transaction or research findings.